These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26066774)

  • 1. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
    Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
    Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
    Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
    Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
    De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
    Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
    Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
    J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
    Park Y; Kim DS; Park KH; Baek SK; Kwon SY; Shin SW; Jung KY; Kim CY; Kim YH; Lee NJ; Kim JS; Kim IS
    Onkologie; 2012; 35(11):673-82. PubMed ID: 23147544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
    Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
    Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
    Gao Y; Liu D
    Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors.
    Lima LM; de Souza LR; da Silva TF; Pereira CS; Guimarães AL; de Paula AM; de Andrade Carvalho H
    Histopathology; 2012 Feb; 60(3):489-96. PubMed ID: 22176134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
    Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
    Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.
    Geiger JL; Lazim AF; Walsh FJ; Foote RL; Moore EJ; Okuno SH; Olsen KD; Kasperbauer JL; Price DL; Garces YI; Ma DJ; Neben-Wittich MA; Molina JR; Garcia JJ; Price KA
    Oral Oncol; 2014 Apr; 50(4):311-8. PubMed ID: 24467937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
    Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
    Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
    Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
    Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
    van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
    Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.